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Abstract
Background—Although genetic factors contribute to the onset of heart failure (HF), no large-
scale genome-wide investigation of HF risk has been published to date. We investigated the
association of 2,478,304 single nucleotide polymorphisms (SNPs) with incident HF by meta-
analyzing data from 4 community-based prospective cohorts: the Atherosclerosis Risk in
Communities Study, the Cardiovascular Health Study, the Framingham Heart Study, and the
Rotterdam Study.
Methods and Results—Eligible participants for these analyses were of European or African
ancestry and free of clinical HF at baseline. Each study independently conducted genome-wide
scans and imputed data to the ~2.5 million SNPs in HapMap. Within each study, Cox proportional
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hazards regression models provided age- and sex-adjusted estimates of the association between
each variant and time to incident HF. Fixed-effect meta-analyses combined results for each SNP
from the 4 cohorts to produce an overall association estimate and p-value. A genome-wide
significance p-value threshold was set a priori at 5.0×10−7. During a mean follow-up of 11.5
years, 2,526 incident HF events (12%) occurred in 20,926 European-ancestry participants. The
meta-analysis identified a genome-wide significant locus at chromosomal position 15q22
(1.4×10−8), which was 58.8 kb from USP3. Among 2,895 African-ancestry participants, 466
incident HF events (16%) occurred during a mean follow-up of 13.7 years. One genome-wide
significant locus was identified at 12q14 (6.7×10−8), which was 6.3 kb from LRIG3.
Conclusions—We identified 2 loci that were associated with incident HF and exceeded
genome-wide significance. The findings merit replication in other community-based settings of
incident HF.
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Heart failure (HF) is a serious cardiovascular condition that affects 1 in 5 people during their
lifetime.1 Failure arises primarily from the burden of systemic hypertension, coronary
ischemia, or cardiac valvular disease.2, 3 Regardless of the clinical mechanism responsible
for reduced cardiac output in HF, long-term strain triggers maladaptive cellular function and
growth, possibly resulting in irreversible myocardial injury.4,5
Genetic factors contribute to HF onset, and an estimated ~18% of the risk of HF may be
attributable to parental HF.6 To date, approaches to identifying genetic variants associated
with HF risk have relied on candidate genes, primarily those of the renin-angiotensin-
aldosterone system, adrenergic receptors, and sarcomeres and cytoskeletal proteins.7, 8 No
large-scale genome-wide investigation of HF risk has been published.9 This report presents
findings from an investigation of ~2.5 million single nucleotide polymorphisms (SNP) and
their associations with incident HF among 23,821 adults of European or African ancestry.
Methods
Setting
The setting for this meta-analysis is the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium and includes data from 4 prospective, population-
based cohorts of adults in the US and the Netherlands: the Atherosclerosis Risk in
Communities (ARIC) Study, the Cardiovascular Health Study (CHS), the Framingham
Heart Study (FHS), and the Rotterdam Study (RS).10 The designs of these studies have been
described elsewhere.11–16 Briefly, ARIC recruited 15,792 participants 45–64 years of age
from 1987 to 1989 from 4 US communities. The Cardiovascular Health Study recruited
participants 65 years of age and older from 4 US communities in 2 waves: 5,201 participants
in 1989–1990, and an additional 687 African Americans in 1992–1993. The Framingham
Heart Study recruited 2 generations of participants 28–72 years of age in 2 time periods:
5,209 Original Cohort participants were recruited in 1948 from Framingham, Massachusetts;
and 5,124 Offspring Cohort participants were recruited in 1971–1975. The Rotterdam Study
recruited 7,983 participants 55 years of age and older from 1990 to 1993 from Rotterdam,
the Netherlands. The ARIC and CHS studies included African-American participants, 27%
and 15%, respectively, while FHS and RS were almost exclusively participants of European
ancestry. Each study independently conducted genome-wide scans of study participants and
within-study analyses were conducted according to a pre-specified plan and results were
combined for this prospective meta-analysis.
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Eligible participants for these analyses were of European or African ancestry and free of
clinical HF. Details about cohort-specific methods for ascertaining prevalent HF at baseline
have been published elsewhere.6, 17–20 Race was self-reported. Each study received IRB
approval and all participants provided written informed consent for the use of their DNA for
research.
Measures
Baseline—For this analysis, baseline measures of clinical and demographic characteristics
were obtained at the time of cohort entry for ARIC, CHS, and RS, and at the time of DNA
collection for FHS. Measures were taken using standardized methods as specified by each
study and included in-person measures of height, weight, systolic and diastolic blood
pressure, and total cholesterol; self-reported history and treatment of hypertension and
diabetes; and self-reported history of prevalent coronary artery disease (CAD, including a
history of myocardial infarction [MI], angina, or coronary revascularization) and
cerebrovascular disease (stroke or transient ischemic attack). For CHS, FHS, and RS,
prevalent cardiovascular disease was validated by medical record review.
Follow-up and Heart Failure Diagnosis—Potential incident HF events were identified
during follow-up by annual or semi-annual self-report, from administrative data, or from
periodic in-study examinations. Briefly, ARIC relied on ICD-9 codes collected from hospital
discharge summaries and death certificates.20, 21 For CHS, FHS, and RS, HF events
identified by self-report or administrative data were validated by physician review of
medical records. CHS and Framingham applied their published criteria,22, 23 and RS applied
the European Society of Cardiology criteria.18, 24 Details can be found in supplemental
Table S1 and in previously published reports.
Genotyping and Imputation—Genotyping used DNA collected from phlebotomy.
Genome-wide assays of SNPs were conducted independently in each cohort using various
technologies: Affymetrix 6.0 for ARIC, Illumina 370CNV for CHS, Affymetrix 500K and
50K for FHS, and Illumina 550K v3 for RS. Genotype quality control and data cleaning
were conducted independently by each study and are summarized in Supplemental Table S2.
Methods were very similar across studies and reflect those used in other published reports
on genome-wide associations.25, 26
We investigated genetic variation in the 22 autosomal chromosomes. For European-ancestry
participants, each study independently imputed their genotype data to the ~2.5 million SNPs
identified in HapMap CEU samples.27, 28 For African-ancestry participants, CHS imputed
to combined CEU and YRI samples and ARIC did not impute. Supplemental Table S2
provides details about the imputation methods for each cohort and the quality control criteria
applied to the imputed genotypes. Imputation results were summarized as an “allele dosage”
defined as the expected number of copies of the minor allele at that SNP (a continuous value
between 0 and 2) for each genotype. Each cohort calculated a ratio of observed versus
expected variance (OEV) of the dosage statistic for each SNP. This value, which generally
ranges from 0 to 1 (poor to excellent), is a measure of imputation quality. High-signal SNPs
that had low OEV values in CHS (<0.8) were directly measured to improve the quality of
the signal. No other cohort conducted additional genotyping.
Statistical Analyses
Investigators from all cohorts jointly developed the pre-specified analytic plan. Within each
study, Cox proportional hazards regression models were used to test the association between
each SNP and time to incident HF while adjusting for sex and baseline age. Time-to-event
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models are standard for longitudinal study designs. CHS adjusted for study site. FHS
adjusted for generation, and for ancestry using principal components. 29 Time of entry to the
analysis was the date of cohort entry (ARIC, CHS, RS) or DNA collection (FHS) and failure
time was the time of HF diagnosis. Participants without incident HF were censored at the
time of death, last date of contact, or at the end of follow-up, whichever came first. For each
SNP, additive genetic models were used to estimate the regression coefficient for the hazard
ratio (HR) for allele dosage, and its respective standard error. In ARIC and CHS, analyses
were conducted separately in 2 ancestry groups, European and African. For each analysis, a
genomic control coefficient (λ) was calculated, that estimated the extent of underlying
population structure.
Meta-analyses were performed using MetABEL software
(http://mga.bionet.nsc.ru/~yurii/ABEL/).30 For the populations of European ancestry, fixed-
effect meta-analyses combined regression β coefficients and λ-adjusted standard errors
across the 4 cohorts for each SNP to produce an overall β coefficient, standard error, and p-
value. We found that asymptotic assumptions of survival analysis models were not accurate
when the number of cases carrying the variant allele was small, so we excluded SNPs for
which the post-meta-analysis population-size-weighted minor allele frequency (MAF) was
less than 0.015.
We created a quantile-quantile (Q-Q) plot of the distribution of the observed and expected p-
values associated with the successful SNPs along with a plot of all the p-values according to
location within each of the 22 chromosomes. The a priori threshold of genome-wide
significance was set at 5.0×10−7, also used by the Wellcome Trust Case Control
Consortium.31 For 2.5 million tests, this threshold limits the expected number of genome-
wide false positives to approximately 1. We also report high-signal SNPs that were
associated with p-values of less than 1.0×10−5, the point where observations deviate from
the expected on the Q-Q plot. When more than 1 SNP clustered at a locus, we picked the
SNP with the smallest p-value as the locus marker. Forest plots that included cohort-specific
findings were created for genome-wide significant SNPs.
In sensitivity analyses, we subjected our top associations to time-to-event analyses that
excluded participants with a baseline history of clinical MI and censored those with an
incident MI during follow-up. This approach allowed us to estimate the association of
selected SNPs and HF onset among participants whose HF was less likely to be ischemic in
origin.
For participants of African ancestry, a similar analytic approach was undertaken in ARIC
and CHS. The ARIC cohort did not have imputed data on those of African ancestry so
testing was restricted to successfully genotyped SNPs on their Affymetrix 6.0 chip that had
an average weighted MAF of at least 0.075 in meta-analyses. Genome-wide significance
was set at 5.0×10−7. High-signal SNPs from the meta-analysis in the European- and
African-ancestry populations were compared.
Results
A total of 20,926 eligible participants of European ancestry and 2,895 participants of
African ancestry were free of HF at cohort entry and had genome-wide data that met cohort-
specific quality control measures. Characteristics of the 23,821 cohort participants included
in these analyses are provided in Table 1. The average age ranged from 53.3 to 72.6 for the 4
cohorts, and the majority of the participants were women (57%). Other demographic and
clinical characteristics were similar across the 4 cohorts. A total of 2,526 incident HF events
(12.1%) were identified over a weighted average of 11.5 years of follow-up among those of
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European ancestry and 466 events (16.1%) over a weighted average of 13.7 years among
those of African ancestry. The average age at the time of HF onset was 73.6 years (range 44
to 101) and 52% of the 2,992 events occurred among women. Among European and African
ancestry participants, 73% and 78%, respectively, of the events were diagnosed in the
absences of a prior MI.
Participants of European Ancestry
A total of 2,478,304 SNPs were investigated across the 4 cohorts. The λ coefficients for
analyses of European participants in each of the 4 cohorts were small (≤1.03) and suggested
negligible test statistic inflation. Supplemental Figure 1A presents the Q-Q plot of meta-
analyzed p-values derived from the 2,478,304 tests performed plotted against the expected
distribution. Overall, evidence for population admixture was small (λ = 1.02). At the lowest
p-values, the observed exceeded the expected.
Figure 1A presents all 2,478,304 p-values organized by chromosome and genomic position.
Among these SNPs, 5 exceeded the genome-wide significance threshold (5.0×10−7) and
marked 2 loci, 1 on chromosome 13 (13q22) and the other on chromosome 15 (15q22). (See
Supplemental Table S3.) Top SNPs at both loci were poorly imputed in CHS so each was
genotyped. After inclusion of the newly measured SNPs in CHS, only the 15q22 locus
retained genome-wide significance. An additional 12 loci on 9 chromosomes were marked
by 28 SNPs with p-values less than 1.0×10−5. (See Supplemental Table S3.) Top SNPs for 7
loci were poorly imputed in CHS so these were genotyped. Among the 7 SNPs, 3 retained a
p-value less than 1.0×10−5 after inclusion of newly measured SNPs. Table 2 lists the top
SNP for each of the 9 loci, after genotyping in CHS.
Genome-wide Significant Locus in European-Ancestry Participants—
Chromosomal position 15q22 was marked by 1 SNP, rs10519210, which had a MAF of
0.032 and was associated with a p-value of 1.4×10−8. The HR for this SNP was 1.53 per G
allele. This SNP is located between 2 genes: 58.8 kb from USP3 (ubiquitin specific
peptidase 3) and 63.9 kb from CA12 (carbonic anhydrase XII). Figure 2a presents detailed
information about the LD and p-values of regional markers for this locus. This SNP was
genotyped in 1 population (ARIC) and imputed in the 3 others. The cohort-specific
estimates are provided in Table 3 and Figure 3a. Risk estimates were generally consistent
across cohorts.
There were 19,195 participants of European ancestry at risk for HF who did not have a
history of clinical MI at baseline. Among these participants, 1,854 had an incident HF event
without a prior incident MI during follow-up. For locus 15q22 (rs10519210), the p-value
and the HR were diminished slightly but similar to findings for all HF events: p-value =
2.8×10−6 and HR = 1.51 (see supplemental Table S4).
Loci with a P-value <1.0×10−5 in European-Ancestry Participants—Nine
additional loci on chromosomes 1, 3, 7, 8, 9, 10, 12, 13 and 19, were associated with SNPs
that had p-values less than 1.0×10−5 (Tables 2 and S3). Among the 9, 2 loci were intronic:
rs11118620 (MAF = 0.292) in LOC100129376 and rs11880198 (MAF = 0.134) in GNA15
(guanine nucleotide binding protein [G protein], alpha 15 [Gq class]). Four loci were close
to known genes: rs13225783 (MAF = 0.048) within 43.9 kb of EVX1 (even-skipped
homeobox 1); rs10812610 (MAF = 0.496) within 4.1 kb of MOBKL2B (MOB1, Mps One
Binder kinase activator-like 2B) and 4.1 of IFNK (interferon, kappa); rs11203032 (MAF =
0.103) within 1.1 kb of CH25H (cholesterol 25-hydroxylase) and 8.7 kb of LIPA (lipase A,
lysosomal acid, cholesterol esterase), and rs548097 (MAF = 0.018) within 82.5 kb of
TBC1D4 (TBC1 domain family, member 4). The remaining 3 loci were not within 100 kb of
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known genes and nearest genes were BCHE (butyrylcholinesterase) for rs1523288, SNX16
(sorting nexin 16) for rs6473383, and PRICKLE1 (prickle homolog 1) for rs1520832.
Supplemental Figures S2a-i present detailed information about the LD and p-values of
regional markers for these 9 loci. Cohort-specific details on these loci are presented in Table
3, and sensitivity analyses restricted to those without a prior MI are presented in
Supplemental Table S4.
Participants of African Ancestry
A total of 692,330 SNPs were investigated across the 2 cohorts that included participants of
African ancestry. The λ coefficients were small (<1.02) and suggested negligible population
structure. Supplemental Figure 1B presents the Q-Q plot from the 692,330 tests performed
and Figure 1B presents all p-values organized by chromosome and position. No SNP had a
p-value that exceeded the genome-wide significance threshold (5.0×10−7). Seven loci on 4
chromosomes were marked by 10 SNPs with p-values less than 1.0×10−5. (See
Supplemental Table S3.) Five loci were marked by poorly imputed SNPs in CHS and 2 of
these were genotyped. Among the 2, 1 reached genome-wide significance (12q14) and 1 did
not retain a p-value less than 1.0×10−5. Table 2 lists the top SNP for the 6 loci with a p-
value less than 1.0×10−5.
Genome-wide Significant Locus in African-Ancestry Participants—
Chromosomal position 12q14 was marked by 1 SNP, rs1172782, which had a MAF of 0.29
and was associated with a p-value of 6.7×10−8. The HR for this SNP was 1.46 per G allele.
This SNP is located 6.3 kb from LRIG3 (leucine-rich repeats and immunoglobulin-like
domains 3). Figure 2b presents detailed information about the LD and p-values of regional
markers for this locus. The cohort-specific estimates are provided in Table 3 and Figure 3b.
Risk estimates were consistent across both cohorts.
There were 2,631 participants of African ancestry at risk for HF who did not have a history
of clinical MI at baseline. Among these participants, 372 had an incident HF event without a
prior incident MI during follow-up. For locus 12q14 (rs1172782), the p-value and the HR
were similar to findings for all HF events: p-value = 6.5×10−8 and HR = 1.53 (see
supplemental Table S4).
Loci with a P-value <1.0×10−5 in African-Ancestry Participants—Five loci on
chromosomes 2, 9, 11 and 12 were associated with SNPs that had p-values less than
1.0×10−5 (Table 2). Two loci were close to hypothesized or known genes: rs13418717
(MAF = 0.202) within 4.8 kb of LOC339760 and rs563519 (MAF = 0.344) within 43.6 kb
of RPUSD4 (RNA pseudouridylate synthase domain containing 4). The remaining 3 loci
were not within 100 kb of known genes and nearest genes were SH3GL2 (SH3-domain
GRB2 [growth factor receptor-bound protein 2]-like 2) for rs2210327, TMTC1
(transmembrane and tetratricopeptide repeat containing 1) for rs2046383, and BTG1 (B-cell
translocation gene 1, anti-proliferative) for rs17019682. Supplemental Figures S2j-n present
detailed information about the LD and p-values of regional markers for the 5 loci. Cohort-
specific details on these loci are presented in Table 3 and sensitivity analyses restricted to
those without a prior MI are presented in supplemental Table S4.
Across-Ancestry Comparisons
The genome-wide significant SNP in European-ancestry participant, rs10519210, was not
associated with HF in those of African ancestry: 7.6×10−1 (HR = 1.06; MAF = 0.179). The
genome-wide significant SNP in African-ancestry participant, rs11172782, was uncommon
and not associated with HF in those of European ancestry: 5.6×10−1 (HR = 0.91; MAF =
0.018).
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From among the 9 high-signal SNPs identified in European-ancestry participants, none was
genotyped in ARIC and therefore none was included in African-ancestry genome-wide
analyses. When these 9 SNPs were examined in CHS participants of African ancestry, 1 of
the 9 SNPs was associated with a p-value of less than 0.05: rs10812610 had a p-value of
9.1×10−3 (HR = 1.52; MAF = 0.766 [C allele was not minor allele in these participants]).
When meta-analyzed with the European-ancestry findings, the resulting combined-ancestry
p-value for this locus was 7.5×10−7. From among the 5 high-signal SNPs in African-
ancestry participants, none was associated with HF risk in European-ancestry participants
(all p-values >5.0×10−2).
Comments
Among 20,926 European-ancestry participants with 2,526 incident HF events, we identified
1 locus with a SNP whose p-value (1.4×10−8) exceeded the genome-wide statistical
significance threshold of 5×10−7 and was associated with a 53% increase in HF risk. Among
2,895 African-ancestry participants who had 466 incident events, we identified 1 locus with
a SNP whose p-value (6.7×10−8) exceeded the genome-wide statistical significance and was
associated with a 46% increase in HF risk. For both loci, risk estimates were similar for
those subjects who HF was not attributable to MI. We identified an additional 14 loci in
European-ancestry and African-ancestry participants that were marked by high-signal SNPs,
p-value less than 1.0×10−5, but that did not reach genome-wide significance. For most loci,
risk estimates were modest and did not appear to differ in a subject of participants without
an MI preceding HF onset.
Genes Associated with Genome-wide Significant and High-Signal Findings
Our results suggest that there may be several genomic regions associated with new-onset HF
in older adults, and support the hypothesis that common genetic variation, regardless of the
clinical mechanism responsible for reduced cardiac output in HF, contribute to risk. The 2
loci with marker SNPs that reached genome-wide significance were within 60kb of known
genes: USP3 and CA12 in European-ancestry participants and LRIG3 in African-ancestry
participants. The product of the USP3 gene is a ubiquitin-specific protease (USP). Ubiquitin
is a highly conserved 76-amino acid protein involved in the regulation of intracellular
protein breakdown, cell cycle regulation, and stress response. It is released from degraded
proteins by disassembly of the polyubiquitin chains, which is mediated by USPs.32 The
USP3 gene may also have a role in genome stability.33 The gene product from CA12 is a
membrane protein highly expressed in many tissue beds and may have a role in cancer
prognosis.34 The LRIG3 gene is a member of the LRIG family of genes that is widely
expressed and impacts tissue development and tumor progression 35–37
Among the 14 high-signal SNPs, 2 were intronic, 1 of which in a known gene, GNA15, and
1 in hypothetical gene LOC100129376. The GNA15 gene, marked by rs11880198, is a
guanine nucleotide binding protein of the Gq class, found in some G-protein-coupled
receptors. This family of receptors include adrenergic, endothelin, and angiotensin II
receptors, which regulate cardiac output, arterial pressure, and blood volume.38, 39 Three
important amino acid substitutions (1 nonsense, 2 missense) and 1 frame shift variant have
been identified in the GNA15 gene. None of these variants were included in the imputed
SNP panel and LD with the HF SNP in our data is not known. Two additional high-signal
SNPs were within 10kb of known genes, which included MOBKL2B and IFNK, and CH25H
and LIPA. None appears to have known functional qualities related to cardiac processes.40,
41 Three additional high-signal SNPs were within 100kb of known genes including EVX1,
TBC1D4, and RPUSD4. Several papers have been published on the protein product of the
TBC1D4 gene, known as AS160, and its role in handling insulin in skeletal muscles.42–44
The remaining 6 SNPs were not within 100 kb of genes.
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Although we have described genes nearest to high-signal markers as potential culprits in the
observed associations it is possible that the true casual variant—if one exists—lies in
neighboring genes or within non-protein coding transcripts in intergenic regions.45 In this
article, we have identified the genes nearest to the high-signal marker as good candidates but
identifying the true causal genes will require further scientific investigation.
The consistency of findings across the European-ancestry and African-ancestry populations
was modest at best. For the 2 genome-wide significant findings, the MAFs differed greatly
between African-ancestry and European-ancestry participants. These high signal markers are
probably not themselves causal and are likely to be in linkage disequilibrium with the causal
variants. In view of the large differences in MAFs and the different patterns of LD between
the populations, it is perhaps not surprising that the associations are not consistent across
ancestral groups. Indeed, the optimal replication sample for the findings in those of
European ancestry would be other similar populations of European ancestry.
Strengths and Limitations
This is the first large-scale attempt to discover genetic risk variants for incident HF, and
included more than 23,000 individuals and ~2.5 million markers spread throughout the
genome. Data came from 4 large, population-based cohort studies that included
cardiovascular outcomes as primary study endpoints. Over 2,500 incident HF events among
European-ancestry participants were included in our analyses which allowed 80% power (2-
sided α=5×10−7) to detect HRs as small as 1.6, 1.4, and 1.3 for variants with a MAF of 0.05,
0.1, and 0.2, respectively. For African-ancestry participants, minimal detectable HRs were
larger: 2.6, 2.2, and 1.9, respectively. Statistical power for African-ancestry analyses was
limited. We found 1 SNP of genome-wide significance for each ancestry population, on par
with what one would expect by chance alone. Replication of associations between these
SNPs and incident HF will clarify what role—if any—these SNPs have in the genesis of
clinical HF. Each cohort relied on slightly different criteria to classify HF events and it was
not feasible to reclassify all 2,992 events using a standard protocol. The between-study
variation in HF classification likely introduced some heterogeneity that may have
diminished our power to detect associations. Furthermore, we did not have comparable and
complete data across cohorts on the type of failure. Previously published data from CHS and
FHS indicate that half of patients with new-onset HF have cardiac systolic dysfunction at the
time of clinical onset.46, 47 Not all 2,478,304 variants tested in those of European ancestry
were directly genotyped and the imputation quality varied across SNPs. For poorly imputed
SNPs there was reduced statistical power to detect an association. We excluded SNPs with
low MAF from meta-analyses since asymptotic assumptions of survival analysis models
may not be accurate if the number of cases with the variant allele is low. For European-
ancestry participants, the MAF threshold of 0.015 translates to ~75 participants with incident
HF who are carriers of 1 or more variant alleles. This relatively large number of events is
not expected to violate asymptotic assumptions and p-values are likely accurate. Most of the
across-ancestry comparisons were limited to data from CHS, where imputation quality for
African-ancestry participants was generally poor because the Illumina 370CNV chip was not
designed to optimize coverage in this ancestry.
Summary
Using data from 4 prospective cohort studies that included 23,821 participants and
prospectively identified 2,992 incident HF events in older adults, we identified 2 SNPs that
reached genome-wide significance, 1 in European-ancestry and 1 in African-ancestry
participants. An additional 14 sub-threshold but high-signal loci were identified and
included intronic markers in attractive candidate genes. Our findings merit replication in
other community-based settings of incident HF.
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Genetic factors contribute to heart failure (HF) onset and, to date, most approaches to
identifying genetic variants associated with HF risk have relied on candidate genes. No
large-scale genome-wide investigation of HF risk has been published. We investigated
the association of ~2.5 million single nucleotide polymorphisms (SNPs) with incident HF
by meta-analyzing data from 4 community-based prospective cohorts: the
Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, the
Framingham Heart Study, and the Rotterdam Study. Among 20,926 European-ancestry
participants with 2,526 incident HF events, we identified 1 locus with a SNP whose p-
value (1.4×10−8) exceeded the genome-wide statistical significance threshold of 5×10−7
and was associated with a 53% increase in HF risk. Among 2,895 African-ancestry
participants who had 466 incident events, we identified 1 locus with a SNP whose p-
value (6.7×10−8) exceeded the genome-wide statistical significance and was associated
with a 46% increase in HF risk. We identified an additional 14 loci in European-ancestry
and African-ancestry participants that were marked by high-signal SNPs, p-value less
than 1.0×10−5. For most loci, risk estimates were modest and did not appear to differ in
subjects without an MI preceding HF onset. Our results suggest that there may be several
genomic regions associated with new-onset HF in older adults, and support the
hypothesis that common genetic variation, regardless of the clinical mechanism
responsible for reduced cardiac output in HF, contribute to risk. These findings merit
replication in other community-based settings of incident HF.
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Figures 1a–b. The log, base-10, p-value of the additive genetic model for each single
nucleotide polymorphisms with a minor allele prevalence of greater than or equal to 1.5% %
for European-ancestry participants (1a) and 7.5% for African-ancestry participants (1b)
according to location in the 22 autosomal chromosomes. Horizontal line indicates the
5×10−7 threshold of genome-wide significance.
Smith et al. Page 14














Figures 2a–b. Regional plots for genome-wide significant marker loci: 2a. rs10519210 in
European-ancestry participants; 2b. rs11172782 in African-ancestry participants. The SNP
with the smallest p-value is presented in black font and neighboring variants are presented in
different black saturations based on linkage disequilibrium: dark gray: r2 ≥ 0.5 and <0.8;
light gray: r2 ≥ 0.2 and < 0.5; and white: r2 < 0.2. There were no SNPs in the region with a
linkage disequilibrium r2 ≥ 0.8 with the top hit.
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Figures 3a–b. Meta-analysis and study-specific β-coefficients and confidence intervals
(α=0.0000005) for genome-wide significant findings for genome-wide significant single
nucleotide polymorphisms: 3a. rs10519210 in European-ancestry participants; 3b.
rs11172782 in African-ancestry participants.
Smith et al. Page 16










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Circ Cardiovasc Genet. Author manuscript; available in PMC 2011 June 1.
